ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)

ANNALS OF ONCOLOGY

ELSEVIER

1. Innovent Biologics, Inc.
2. Eli Lilly and Company